Melio
PrivateLast Round
Grant
Jan 14, 2025
Total Funding Raised
$10.7M
Company Overview
Melio operates in Healthcare & Life Sciences and is based in Santa Clara, California. Its latest recorded funding round was a Grant round in January 2025.
Melio is a biotechnology company developing a rapid, culture-free bloodborne pathogen testing platform that integrates proprietary assays, microfluidics, and machine learning to identify infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Biotech Equipment, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Melio Comparables
Compare Melio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HelixBind | 84% | |
| Vivid Dx | 82% | |
| Microbio | 81% |
For institutional investors. Book with your work email.
Melio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 14, 2025 | ||||
| Seed | Jun 30, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Melio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lexi Ventures | Seed |
| MIT Alumni Angels of Northern California | Seed |
| CARB-X | Grant, Seed |
| Catalytic Impact Foundation | Seed |
| Cove Fund | Seed |
| Little Green Bamboo Capital | Seed |
| LongeVC | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2025
Grew 20% QoQ, from 30 to 36 employees.
- May 11, 2025
Grew 17% QoQ, from 30 to 35 employees.
For institutional investors. Book with your work email.
Melio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Melio's valuation, stock price, and market status.
Is Melio a public or private company?
Melio is a private company.
What is the current stock price of Melio?
Melio is a private company, so its shares have no public market price. Caplight tracks Melio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Melio worth (valuation)?
Valuation information for Melio is not publicly available.
Can I buy Melio stock?
Melio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Melio's last funding round?
Melio's most recent funding round was Grant on January 14, 2025.
Who are the main investors in Melio?
Key investors in Melio include Lexi Ventures, MIT Alumni Angels of Northern California, CARB-X, Catalytic Impact Foundation, Cove Fund.
Will Melio IPO soon?
No public IPO plans have been announced for Melio.
How can I track Melio secondary market activity?
Caplight tracks bids, offers, and trades in Melio's shares on secondary markets.